Agilent (A) Offering Possible 17.37% Return Over the Next 27 Calendar Days

Agilent’s most recent trend suggests a bearish bias. One trading opportunity on Agilent is a Bear Call Spread using a strike $72.50 short call and a strike $77.50 long call offers a potential 17.37% return on risk over the next 27 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $72.50 by expiration. The full premium credit of $0.74 would be kept by the premium seller. The risk of $4.26 would be incurred if the stock rose above the $77.50 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Agilent is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Agilent is bearish.

The RSI indicator is at 36.92 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Agilent

Agilent to Acquire BioTek, Cell Analysis Portfolio to Expand
Fri, 12 Jul 2019 13:35:01 +0000
Agilent Technologies (A) enters into an agreement to buy BioTek Instruments, which is likely to strengthen its cell analysis capabilities and expand presence in life science research space.

Agilent Technologies, Inc. (NYSE:A): Earnings Expected To Remain Subdued
Fri, 12 Jul 2019 11:29:31 +0000
Since Agilent Technologies, Inc. (NYSE:A) released its earnings in April 2019, analyst consensus outlook seem bearish…

Agilent Technologies, Inc. — Moody’s: Agilent Technologies’ acquisition of BioTek increases leverage, but adds complementary growth driver
Thu, 11 Jul 2019 23:32:07 +0000
Moody’s Investors Service commented that Agilent Technologies Inc.’s announcement that it has agreed to acquire BioTek Instruments for $1.17 billion is strategically sound, adding to Agilent’s rapidly growing cell analysis franchise. There is no change to Agilent’s Baa2 senior unsecured rating or stable outlook, given Agilent’s strong overall financial profile and Moody’s expectations for deleveraging over the next 12 to 18 months. For additional information, please refer to Moody’s issuer comment on Agilent Technologies Inc. available on

Blue Lion To Sell Back All Its HomeStreet Shares
Thu, 11 Jul 2019 14:38:29 +0000
Blue Lion Group will sell all of its shares of HomeStreet, Inc. (NASDAQ: HMST ) common stock to the company. The group owns approximately 6.48% of the HomeStreet’s common stock. Under the share purchase …

Agilent Will Acquire BioTek Instruments In $1.16B Deal
Thu, 11 Jul 2019 12:16:33 +0000
Agilent (NYSE: A ) will acquire BioTek Instruments in a $1.165 billion deal. The transaction is expected to be completed in Agilent’s fiscal fourth quarter. BioTek designs, manufactures and distributes …

Be Sociable, Share!

Related Posts